Abstract: A pharmaceutical solution composition includes: a therapeutically effective amount of molnupiravir or a metabolite thereof, and a solvent. An oral mist inhaler includes: a soft mist inhaler and the pharmaceutical solution composition, wherein the soft mist inhaler is loaded with the pharmaceutical solution composition. The pharmaceutical solution composition is highly stable and produces a relatively small amount of impurities. The oral mist inhaler allows a user to inhale the pharmaceutical solution composition directly so that not only can the composition be rapidly absorbed, but also the metabolic process that the drug must go through is reduced to enhance the bioavailability of the drug. The particles formed by the soft mist inhaler atomizing the composition are small and sprayed in a large amount. Compared with the conventional oral administration method, the oral mist inhaler is easy to use and helps improve the comfort and convenience of medicine consumption.

Abstract: A method of preventing HIV-1 associated dendritic pathology in a brain cell, comprising contacting the cell with a therapeutically effective dose of a mitochondrial ATP-sensitive potassium channel agonist. A method of preventing HIV-1 associated dendritic pathology in a brain cell, comprising contacting the cell with a therapeutically effective dose of an inhibitor of succinate dehydrogenase. A method of preventing HIV-1 associated dendritic pathology in a brain cell, comprising contacting the cell with a therapeutically effective dose of a stimulator of production of reactive oxygen species. A model for the study of HIV-1 associated dendritic pathology, comprising a) contacting a hippocampal slice with platelet-activating factor; and b) stimulating the hippocampal slice of a) with high frequency stimulation.